Certolizumab pegol in rheumatoid arthritis: Current update

Expert Opinion on Biological Therapy

Volumn 14, Issue 6, 2014, Pages 841-850

  Fechtenbaum, Marie ^a,b   Md Yusof, Md Yuzaiful ^a,b   Emery, Paul ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Anti TNF; Biological therapy; Certolizumab; PEGylation; Rheumatoid arthritis

Indexed keywords

BIOSIMILAR AGENT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION; INFECTION RISK; INJECTION SITE REACTION; MONOTHERAPY; RADIOGRAPHY; REMISSION; RHEUMATOID ARTHRITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG COMBINATION; IMMUNOLOGY; METABOLISM; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; POLYETHYLENE GLYCOLS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900822066     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.900043     Document Type: Article

References (53)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27(2):269-81
2. Furneri G, Mantovani LG, Belisari A, et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30(4 Suppl 73):S72-84
3. Alsalameh S, Winter K, Al-Ward R, et al. Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers. Scand J Immunol 1999;49(3):278-85
4. Bluml S, Scheinecker C, Smolen JS, Redlich K. Targeting TNF receptors in rheumatoid arthritis. Int Immunol 2012;24(5):275-81
5. Smolen JS, Aletaha D, Redlich K. The pathogenesis of rheumatoid arthritis: new insights from old clinical data? Nat Rev Rheumatol 2012;8(4):235-43
6. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;(4):CD007848
7. Kristensen LE, Jakobsen AK, Bartels EM, et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scand J Rheumatol 2011;40(1):1-7
8. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-509
9. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9(3):164-72
10. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117(2):244-79
11. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13(11):1323-32
12. Mahadevan U, Abreu MT. 960 certolizumab use in pregnancy: low levels detected in cord blood. Gastroenterology 2009;136:146
13. Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009;348(1-2):36-41
14. EMEA/H/C/001037. Cimzia: european Public Assessment Report, Summary of Product Characteristics. London, UK: European Medicines Agency. 2010. Updated on January 2014. Available from: http://www.ema.europa. eu/docs/en-GB/document- library/EPAR-Product-Information/human/001037/WC500069763.pdf [Last accessed 12 January 2014]
15. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68(6):805-11
16. Weinblatt ME, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology 2012;51(12):2204-14
17. Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58(11):3319-29
18. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68(6):797-804
19. van der Heijde D, Keystone EC, Curtis JR, et al. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol 2012;39(7):1326-33
20. Emery P, Furst DE, Keystone EC, et al. Certolizumab pegol remains equally efficacious in the treatment of rheumatoid arthritis over a range of background methotrexate regimens (10-30 mg/wk): analysis of the RAPID 1 trial. Ann Rheum Dis 2010;67(Suppl 1):180
21. Keystone E, Landewe R, van Vollenhoven R, et al. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis 2013. [Epub ahead of print]
22. Smolen JS, van Vollenhoven R, Kavanaugh A, et al. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from a 24-week randomized controlled trial and open-label extension study. Arthritis Rheum 2013;65:S988-S89
23. Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65(6):753-9
24. Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29(2):238-47
25. Choy E, McKenna F, Vencovsky J, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology 2012;51(7):1226-34
26. Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol plus methotrexate in japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheumatol 2013. [Epub ahead of print]
27. Smolen JS, Emery P, Ferraccioli GF, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 2014. [Epub ahead of print]
28. Furst D, Shaikh SA, Greenwald MW, et al. Certolizumab pegol plus methotrexate is similarly effective in active rheumatoid arthritis secondary non-responders to anti-TNF inhibitors: post-hoc analysis of a phase IIIb trial. Arthritis Rheum 2012;64(10):S567-S67
29. Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Mod Rheumatol 2013. [Epub ahead of print]
30. Keystone EC, Combe B, Smolen J, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology 2012;51(9):1628-38
31. Ostergaard M, Jacobsson L, Schaufelberger C, et al. Magnetic resonance imaging-assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase IIIb study applying magnetic resonance imaging at week 0, 1, 2, 4, 8 and 16. Arthritis Rheum 2013;65:S842-S42
32. Strand V, Smolen JS, van Vollenhoven RF, et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011;70(6):996-1002
33. Pope J, Fleischmann R, Dougados M, et al. Rapid reductions in fatigue and sleep problems and correlation with improvements in patient-reported outcomes in patients with active rheumatoid arthritis treated with certolizumab pegol in the REALISTIC 12-week phase IIIb randomised controlled study. Rheumatology 2012;51:135-6
34. Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis 2013. [Epub ahead of print]
35. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and cochrane overview. Cochrane Database Syst Rev 2011;(2):CD008794
36. Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut 2009;58(8):1033-9
37. Lamour S, Bracher M, Nesbitt A. PEG component of certolizumab pegol inhibits stimulated mast cell degranulation. Falk Symp 2009;15(12):S28-8
38. Horton S, Walsh C, Emery P. Certolizumab pegol for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2012;12(2):235-49
39. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the british society for rheumatology biologics register with special emphasis on risks in the elderly. Rheumatology 2011;50(1):124-31
40. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52(11):3403-12
41. Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. A longterm, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis 2006;65(12):1578-84
42. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308(9):898-908
43. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68(5):648-53
44. Clowse MEB, Wolf DC, Forger F, et al. Retrospective analysis of certolizumab pegol use during pregnancy: update of impact on birth outcomes. Arthritis Rheum 2013;65:S187-S88
45. Bartelds GM, Wolbink GJ, Stapel S, et al. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006;65(9):1249-50
46. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(3):711-15
47. Thomas S, Borazan N, Duan LW, et al. Comparative immunogenicity of tumor necrosis factor inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum 2013;65:S866-S66
48. Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one antitumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis-results from a large UK national cohort study. Arthritis Rheum 2007;56(1):13-20
49. Nesbitt A, Fossati G, Brown D, et al. Effect of structure of conventional anti-TNFs and certolizumab pegol on mode of action in rheumatoid arthritis. Ann Rheum Dis 2007;66:296-6
50. Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010;49(11):2217-19
51. Nguyen CM, Bounthavong M, Mendes MA, et al. Cost utility of tumour necrosis factor-alpha inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a markov model. Pharmacoeconomics 2012;30(7):575-93
52. Purcaru O, Taylor PC, Emery P, Palmer S. PMS42 cost-effectiveness of certolizumab pegol plus methotrexate or as monotherapy for the treatment of active rheumatoid arthritis in the united kingdom. Value Health 2010;13(7):A310-A10
53. Kavanaugh A, Smolen JS, Emery P, et al. Long-term benefits over more than 4 years of certolizumab pegol combination therapy on workplace and household productivity, and participation in social activities in rheumatoid arthritis: results from the open-label extension study of RAPID1. Value Health 2013;16(7):A570-A70